International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.16 and traded as high as $0.1725. International Stem Cell shares last traded at $0.1725, with a volume of 597 shares trading hands.
International Stem Cell Stock Down 13.2%
The company has a 50 day moving average of $0.18 and a 200-day moving average of $0.16. The stock has a market capitalization of $1.38 million, a P/E ratio of -2.87 and a beta of -0.01.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) EPS for the quarter. The business had revenue of $2.32 million for the quarter.
About International Stem Cell
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Further Reading
- Five stocks we like better than International Stem Cell
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
